# Aster DM Quality Care share price today (Aster DM Quality Care Ltd, NSE: ASTERDM)

> Aster DM Quality Care share price today: ₹681.35 at the NSE close on 3 November 2026, up 0.5% in a year. Aster DM Quality Care (NSE: ASTERDM) is worth ₹59,405 crore, trades at a P/E of 164.1 and has closed between ₹555.25 and ₹869.70 over the past 52 weeks. > Aster DM Quality Care Ltd's share price has risen faster than its earnings: +0.5% in a year, against −93.0% for earnings per share. ASTERDM · Hospitals · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/aster-dm-quality-care-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Getting better, from the last 12 quarters
- Price: ₹681.35 (+0.5% in a year)
- P/E: 164.1× (higher than 97% of the last 8.3 years)
- Revenue (Jun 2026): ₹1,311 Cr (+21.6% on a year ago)
- Profit (Jun 2026): ₹29.0 Cr (−69.1% on a year ago)
- Operating margin: 20.0% (+1.0 points on a year ago)
- ROCE: 12%, FY26
- ROIC: 7.8%, against a 12.0% cost of capital: −4.2 points

The main question: profits are rising, but only 20% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. ## What is the Aster DM Quality Care share price today? Aster DM Quality Care Ltd's share price was ₹681.35 at the close on 3 November 2026. It has been rising for 34 weeks. That is 4.7% below its average price over the last 200 trading days. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 6 weeks running. In the last 52 weeks it traded between ₹555 and ₹870, and at that close it sat 40% of the way up from that low. Over the last 8.7 years the share price moved +295% while the NIFTY 500 moved +145%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 25 September 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Aster DM Quality Care this quarter? Two changes stood out: revenue up on a year earlier for 10 quarters in a row and highest quarterly revenue in 14 quarters. 1. Revenue up on a year earlier for 10 quarters in a row In the June 2026 quarter revenue was ₹1,311 crore, +21.6% on a year earlier. Why: Revenue rose because more patients came in and each patient spent more, helped by treating more complex cases and using beds better. Next results: check whether patient numbers and revenue per patient keep rising, since management expects at least 5 to 6% more patients and 7 to 8% higher revenue per patient. From the earnings call on 5 Aug 2026. 2. Highest quarterly revenue in 14 quarters Revenue of ₹1,311 crore in the June 2026 quarter is the highest of the last 14 quarters. ## What are Aster DM Quality Care's latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Aster DM Quality Care reported revenue of ₹1,311 crore, up 21.6% from ₹1,078 crore a year earlier, and a profit of ₹29.0 crore, down 69.1% from ₹94.0 crore. ### Aster DM Quality Care results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹1,311 crore | ₹1,078 crore | +21.6% |
| Profit | ₹29.0 crore | ₹94.0 crore | −69.1% |
| Earnings per share | ₹0.31 | ₹1.65 | −81.2% |
| Operating margin | 20.0% | 19.0% | +1.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Aster DM Quality Care's management discussed these results on a call held on 5 August 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Aster DM Quality Care share price history? Aster DM Quality Care closed at ₹681.35 on 3 November 2026, up 0.5% from ₹678.05 a year earlier (31 October 2025) and up 251.7% over five years. Its highest weekly close since March 2018 was ₹869.70 on 7 August 2026. ### Aster DM Quality Care share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹644.75 | +5.7% |
| 1 month ago · 1 Oct 2026 | ₹708.90 | −3.9% |
| 6 months ago · 30 Apr 2026 | ₹701.05 | −2.8% |
| 1 year ago · 31 Oct 2025 | ₹678.05 | +0.5% |
| 3 years ago · 3 Nov 2023 | ₹340.85 | +99.9% |
| 5 years ago · 4 Nov 2021 | ₹193.75 | +251.7% |
| Earliest weekly close in our records · 1 Mar 2018 | ₹172.60 | +294.8% |
| Highest weekly close since March 2018, also the 52-week high · 7 Aug 2026 | ₹869.70 | −21.7% |
| Lowest weekly close since March 2018 · 29 May 2020 | ₹89.75 | +659.2% |
| 52-week low (weekly close) · 23 Jan 2026 | ₹555.25 | +22.7% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (460 weekly closes from 1 March 2018 to 3 November 2026.)

## What is the latest news on Aster DM Quality Care? 3 Nov 2026: Aster DM Quality Care closed at ₹681.35, up 5.7% on the week and down 3.9% on the month. 5 Aug 2026: Aster DM Quality Care held its results call for April to June 2026. Management guided: Consolidated operating margin to reach 24-25% between FY28 and FY29. ### Earlier

- Results for April to June 2026: Revenue up 21.6% and profit down 69.1% on a year earlier. - 2 Apr 2026: ex-date for an interim dividend of ₹3 a share, record date 3 Apr 2026. ## What dividend does Aster DM Quality Care pay? Aster DM Quality Care paid ₹3 a share in regular dividends in the 12 months to 4 November 2026 (1 payment), a yield of 0.44% at the ₹681.35 close on 3 November 2026. The last was an interim dividend of ₹3 a share, ex-date 2 April 2026. ### Aster DM Quality Care dividends since 1 April 2021

| Ex-date | Dividend per share | Type | Record date |
| --- | --- | --- | --- |
| 2 Apr 2026 | ₹3 | Interim | 3 Apr 2026 |
| 28 Aug 2025 | ₹1 | Dividend | same day |
| 10 Feb 2025 | ₹4 | Interim | same day |
| 22 Aug 2024 | ₹2 | Dividend | same day |
| 23 Apr 2024 | ₹118 | Special | same day |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 2 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Aster DM Quality Care Ltd paid out 40% of its profit as dividends in FY26, and it paid a dividend in 4 of its last 13 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Aster DM Quality Care management say on the latest results call? On the call for April to June 2026, held on 5 August 2026, Aster DM Quality Care's management guided: Consolidated operating margin to reach 24-25% between FY28 and FY29. > “About a year ago, we said that we hoped to bring in 10-15% incremental EBITDA on account of synergies, and we continue to stand by that.”
> Varun Khanna, on the call for April to June 2026

### What management guided

- Merger synergies planned at 10-15% of FY24 operating profit, equivalent to ₹150-200 crore, with significant results during FY27 and annualization next year. - At least 5-6% organic volume growth and perhaps 7-8% ARPOB growth framed as the operating path to the margin goal. - Add 4,170 beds over 3-4 years to reach 15,000 beds, with 53% brownfield-led. - Medical value travel growth expected above 50%. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/6473/Conference Call/CC-Aug26.pdf). (From the call for April to June 2026, 5 August 2026.)

## What to watch in Aster DM Quality Care's next results? When Aster DM Quality Care reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Synergy contribution to become visible during FY27; check consumption, revenue, cost, and clinical-talent execution in the next print. - What to check (from the call)
- Synergy contribution to become visible during FY27; check consumption, revenue, cost, and clinical-talent execution in the next print. - Consolidated margin progression toward the flagged range; check whether case mix, occupancy, and operating leverage remain supportive. - Aster Capital commissioning and subsequent Hyderabad and Sarjapur milestones; check whether scheduled openings remain on track. - MVT growth to remain ahead of consolidated growth; check whether new geographies and digital lead generation sustain international patient volumes. ## Which stock lists is Aster DM Quality Care on? Aster DM Quality Care is on one of our India lists: Small & mid cap stocks. [Small & mid cap stocks Size rank in India: 167](https://www.sectoralpha.in/small-cap-stocks-india)

## Is Aster DM Quality Care profitable? Aster DM Quality Care Ltd earned ₹29.0 Cr of net profit in the Jun 2026 quarter, −69.1% on the same quarter a year earlier. Full-year FY26 profit was ₹427 Cr. Over 10 years profit has grown 48.8% a year on average. That is 2.2% of the quarter's revenue. The same quarter a year earlier earned ₹94.0 Cr. 2 of the last 12 reported quarters were loss-making. For the full year, FY26 profit was ₹427 Cr (−92.1% on the year before). Why profit moved: revenue changed +21.6% on a year earlier and the margin moved +1.0 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +4.1% and revenue +15.8%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Aster DM Quality Care make, and is it growing? Aster DM Quality Care Ltd reported ₹1,311 Cr of revenue in the Jun 2026 quarter, +21.6% on the same quarter a year earlier. That is the 10th quarter in a row with growth on the year before. Over 10 years it has grown −1.2% a year on average. The last full year, FY26, came in at ₹4,643 Cr. The last four reported quarters add to ₹4,876 Cr. FY26 revenue was ₹4,643 Cr, +12.2% on the year before. Recent pace: the last four quarters grew +15.8% on average, against −1.2% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +15.7%, against +12.4% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +3.7%, against −73.9% a year (accelerating). ## How much of every ₹100 of sales does Aster DM Quality Care keep? Aster DM Quality Care Ltd's operating margin was 20.0% in the Jun 2026 quarter, 1.0 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 13 years it has been between 6.0% and 19.0%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +0.8 percentage points on the year while gross margin changed +0.7 points. So the gain came mostly from the gross margin, which means input costs and prices charged. When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold. ## Is Aster DM Quality Care's profit turning into cash? Over the last 3 years, 20% of Aster DM Quality Care Ltd's reported profit came in as cash from its operations, a gap worth watching. In FY26 it brought in ₹656 Cr of operating cash against ₹427 Cr of profit. After ₹713 Cr of spending on assets, free cash was −₹57.0 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: it has been selling more assets than it buys. The next section shows those figures. ## Where does Aster DM Quality Care's cash go? Aster DM Quality Care Ltd's customer, stock and supplier day counts come out in the thousands of days on sales this small (₹4,643 Cr in FY26), so no cash-cycle chart is drawn and this section looks at its spending on assets instead. Over the last 3 years it sold more assets than it bought, by ₹3,936 Cr. Over the last 3 years, money from selling assets was ₹3,936 Cr more than it spent on new ones. Work still in progress is ₹420 Cr (FY26). In short: assets are being sold, not built, so this cash is not going into new capacity. ## What is Aster DM Quality Care's P/E ratio, and how does it compare with its own history? Aster DM Quality Care Ltd's P/E is 164.1×, near the high end of its own history: higher than 97% of past readings. Its usual P/E (the middle reading) is 42.3×, over 8.3 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹6.15. Why the multiple is where it is: over the past year earnings per share moved −93.0% while the price moved +0.5%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 5 years the price moved +28.6% a year; about −5.6% a year came from earnings growth and about +34.2 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Aster DM Quality Care business getting better or worse? Aster DM Quality Care Ltd's business is getting better. Profit growth hit its low 3 quarters ago at −93.3% and has recovered to +3.7%, with ROCE steady at 9.9%. This is based on 12 quarters of 4 measures. Why it matters: a lasting rise from a low is what this page is built to show. ## How much does Aster DM Quality Care earn on its capital? Aster DM Quality Care Ltd earned a ROCE of 12% in FY26. That is up from a low of 1% in FY17. Its return on capital used (ROIC) is 4.2 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 9.2% net margin and 0.57× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 9.2% net margin × 0.57× asset turnover × 1.92× leverage (assets divided by equity) ≈ 10.1% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 7.8% − 12.0% = −4.2 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Aster DM Quality Care have too much debt? Aster DM Quality Care Ltd has total debt of ₹2,220 Cr against shareholder equity of ₹4,834 Cr as of Jun 2026, so its debt is 0.46× its equity. Year by year, that ratio went from 1.10 in FY22 to 0.46 in FY26. Keep that borrowing in mind when reading the returns on this page. ## What is the Aster DM Quality Care shareholding pattern? Promoters raised their stake in Aster DM Quality Care Ltd by 11.9 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 53.8% of the company. Foreign institutions moved −10.4 points over the same period, to 12.3%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Promoters: +11.9 points over 8 quarters, to 53.8%; Foreign institutions: −10.4 points over 8 quarters, to 12.3%; Domestic institutions: −1.3 points over 8 quarters, to 21.7%. Why the owners changed: promoters drove it (+11.9 points), with the other side taken by foreign institutions (−10.4 points). They raised their stake step by step. ## How far is Aster DM Quality Care from balance-sheet trouble? For Aster DM Quality Care Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Aster DM Quality Care rank in its industry? 35.2 out of 100, rank 16 of 20 in Hospitals, with 96% of the evidence available. Aster DM Quality Care Ltd scores 35.2 out of 100 against the 20 companies it is compared with in Hospitals, ranking 16. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 18.1 + 9 + 1.6 + 6.5 = 35.2. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Aster DM Quality Care compared with? Aster DM Quality Care ranks 16 of 20 Hospitals companies on the 4-Factor Sector Score, with 35.2 out of 100. 1. [KMC Speciality Hospitals (India) Ltd](https://www.sectoralpha.in/stocks/kmc-speciality-hospitals-indialtd) KMCSHIL · breaking out · Sector-leading setup · 81% evidence 80.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.0/35 · Revenue 35.1% · Profit 100% · Operating margin change 6 points · 88% evidence Capital efficiency 23.1/25 · ROCE 26.2% · Operating margin 31% · 100% evidence Valuation 14.1/20 · P/E 43.4× · PEG 0.68 · 100% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 45.6% · 1 year 115.4% · 25% evidence · 5 of 5 weeks ahead Exact sum: 31 + 23.1 + 14.1 + 12.5 = 80.7 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Sakar Healthcare Ltd](https://www.sectoralpha.in/stocks/sakar-healthcare-ltd) SAKAR · leader · Most evidence points up · 100% evidence 68.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.5/35 · Revenue 47.5% · Profit 100% · Operating margin change 8 points · 100% evidence Capital efficiency 11.5/25 · ROCE 12.4% · Operating margin 28% · 100% evidence Valuation 11.1/20 · P/E 49× · PEG 1.05 · 100% evidence Relative strength 13.8/20 · Lead over its industry 41.8% · Lead over NIFTY 500 45.4% · 1 year 161.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 32.5 + 11.5 + 11.1 + 13.8 = 68.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Apollo Hospitals Enterprise Ltd](https://www.sectoralpha.in/stocks/apollo-hospitals-enterprise-ltd) APOLLOHOSP · turning · Most evidence points up · 78% evidence 68.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 17.2% · Profit 33.2% · Operating margin change 1 points · 83% evidence Capital efficiency 15.2/25 · ROCE 17.4% · Operating margin 16% · 76% evidence Valuation 12.7/20 · P/E 57.7× · PEG n/a · 50% evidence Relative strength 16.6/20 · Lead over its industry 6.6% · Lead over NIFTY 500 11.2% · 1 year 10% · 100% evidence · 4 of 12 weeks ahead Exact sum: 24 + 15.2 + 12.7 + 16.6 = 68.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Dr Agarwals Eye Hospital Ltd](https://www.sectoralpha.in/stocks/dr-agarwals-eye-hospital-ltd) DRAGARWQ · breaking out · Evidence leans up · 81% evidence 62.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.1/35 · Revenue 20.1% · Profit 31.6% · Operating margin change -2 points · 88% evidence Capital efficiency 17.4/25 · ROCE 17.2% · Operating margin 30% · 100% evidence Valuation 12.5/20 · P/E 33.7× · PEG 1.36 · 100% evidence Relative strength 11.6/20 · Lead over its industry n/a · Lead over NIFTY 500 9.2% · 1 year 0.8% · 25% evidence · 8 of 12 weeks ahead Exact sum: 21.1 + 17.4 + 12.5 + 11.6 = 62.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Kovai Medical Center & Hospital Ltd](https://www.sectoralpha.in/stocks/kovai-medical-center-hospital-ltd) KOVAI · breaking out · Evidence leans up · 96% evidence 61.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.8/35 · Revenue 15% · Profit 15.8% · Operating margin change 1 points · 88% evidence Capital efficiency 19.1/25 · ROCE 22.6% · Operating margin 29% · 100% evidence Valuation 8.9/20 · P/E 24.8× · PEG 2.01 · 100% evidence Relative strength 14.7/20 · Lead over its industry 1.9% · Lead over NIFTY 500 6.6% · 1 year -9.2% · 100% evidence · 10 of 12 weeks ahead Exact sum: 18.8 + 19.1 + 8.9 + 14.7 = 61.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [GPT Healthcare Ltd](https://www.sectoralpha.in/stocks/gpt-healthcare-ltd) GPTHEALTH · quiet · Evidence leans up · 81% evidence 61.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 15.4/35 · Revenue 18% · Profit 0% · Operating margin change 3 points · 88% evidence Capital efficiency 18.2/25 · ROCE 19.9% · Operating margin 19% · 100% evidence Valuation 18.5/20 · P/E 23× · PEG 0.94 · 100% evidence Relative strength 9.1/20 · Lead over its industry n/a · Lead over NIFTY 500 -2.1% · 1 year -10.7% · 25% evidence · 4 of 12 weeks ahead Exact sum: 15.4 + 18.2 + 18.5 + 9.1 = 61.2 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 7. [Yatharth Hospital & Trauma Care Services Ltd](https://www.sectoralpha.in/stocks/yatharth-hospital-trauma-care-services-ltd) YATHARTH · breaking out · Evidence leans up · 78% evidence 57.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.4/35 · Revenue 43.9% · Profit 22.5% · Operating margin change -2 points · 83% evidence Capital efficiency 12.4/25 · ROCE 12.9% · Operating margin 23% · 76% evidence Valuation 6.7/20 · P/E 49.3× · PEG n/a · 50% evidence Relative strength 19.1/20 · Lead over its industry 17.1% · Lead over NIFTY 500 21.6% · 1 year 16.4% · 100% evidence · 10 of 12 weeks ahead Exact sum: 19.4 + 12.4 + 6.7 + 19.1 = 57.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Artemis Medicare Services Ltd](https://www.sectoralpha.in/stocks/artemis-medicare-services-ltd) ARTEMISMED · leader · Evidence leans up · 100% evidence 56.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.4/35 · Revenue 14.7% · Profit 20% · Operating margin change 0 points · 100% evidence Capital efficiency 12.8/25 · ROCE 14.6% · Operating margin 18% · 100% evidence Valuation 8.0/20 · P/E 39.7× · PEG 2.44 · 100% evidence Relative strength 16.7/20 · Lead over its industry 8.4% · Lead over NIFTY 500 12.9% · 1 year 18.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 19.4 + 12.8 + 8 + 16.7 = 56.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Indraprastha Medical Corporation Ltd](https://www.sectoralpha.in/stocks/indraprastha-medical-corporation-ltd) INDRAMEDCO · quiet · Evidence leans up · 85% evidence 51.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.3/35 · Revenue 10.8% · Profit 10.9% · Operating margin change 0 points · 100% evidence Capital efficiency 17.6/25 · ROCE 35.8% · Operating margin 19% · 100% evidence Valuation 13.2/20 · P/E 14.6× · PEG 1.47 · 100% evidence Relative strength 7.7/20 · Lead over its industry n/a · Lead over NIFTY 500 -19.7% · 1 year -49.6% · 25% evidence · 0 of 12 weeks ahead Exact sum: 13.3 + 17.6 + 13.2 + 7.7 = 51.8 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 10. [Global Health Ltd](https://www.sectoralpha.in/stocks/global-health-ltd) MEDANTA · losing its lead · Evidence leans up · 96% evidence 50.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.5/35 · Revenue 21.3% · Profit 3.4% · Operating margin change -2 points · 88% evidence Capital efficiency 17.3/25 · ROCE 17.4% · Operating margin 22% · 100% evidence Valuation 5.5/20 · P/E 59.7× · PEG 9.11 · 100% evidence Relative strength 14.2/20 · Lead over its industry 3.7% · Lead over NIFTY 500 8.1% · 1 year -3.1% · 100% evidence · 8 of 12 weeks ahead Exact sum: 13.5 + 17.3 + 5.5 + 14.2 = 50.5 · What this means: Relative strength against the index is 8.1%, and revenue and profit growth are weak. 11. [Rainbow Childrens Medicare Ltd](https://www.sectoralpha.in/stocks/rainbow-childrens-medicare-ltd) RAINBOW · quiet · Evidence leans up · 100% evidence 50.3 out of 100 Growth Capital Valuation Relative
12. [Max Healthcare Institute Ltd](https://www.sectoralpha.in/stocks/max-healthcare-institute-ltd) MAXHEALTH · quiet · Evidence leans down · 85% evidence 48.7 out of 100 Growth Capital Valuation Relative
13. [Fortis Healthcare Ltd](https://www.sectoralpha.in/stocks/fortis-healthcare-ltd) FORTIS · basing · Evidence leans down · 78% evidence 45.1 out of 100 Growth Capital Valuation Relative
14. [Shalby Ltd](https://www.sectoralpha.in/stocks/shalby-ltd) SHALBY · quiet · Evidence leans down · 63% evidence 42.0 out of 100 Growth Capital Valuation Relative
15. [Narayana Hrudayalaya Ltd](https://www.sectoralpha.in/stocks/narayana-hrudayalaya-ltd) NH · quiet · Evidence leans down · 78% evidence 40.8 out of 100 Growth Capital Valuation Relative
16. Aster DM Quality Care Ltd this page ASTERDM · quiet · Evidence leans down · 96% evidence 35.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.1/35 · Revenue 15.7% · Profit 3.7% · Operating margin change 1 points · 88% evidence Capital efficiency 9.0/25 · ROCE 11.6% · Operating margin 20% · 100% evidence Valuation 1.6/20 · P/E 164× · PEG 3.1 · 100% evidence Relative strength 6.5/20 · Lead over its industry -2.3% · Lead over NIFTY 500 1.8% · 1 year 0.5% · 100% evidence · 1 of 12 weeks ahead Exact sum: 18.1 + 9 + 1.6 + 6.5 = 35.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 17. [Krishna Institute of Medical Sciences Ltd](https://www.sectoralpha.in/stocks/krishna-institute-of-medical-sciences-ltd) KIMS · quiet · Most evidence points down · 78% evidence 34.8 out of 100 Growth Capital Valuation Relative
18. [Jupiter Life Line Hospitals Ltd](https://www.sectoralpha.in/stocks/jupiter-life-line-hospitals-ltd) JLHL · quiet · Most evidence points down · 100% evidence 33.0 out of 100 Growth Capital Valuation Relative
19. [Healthcare Global Enterprises Ltd](https://www.sectoralpha.in/stocks/healthcare-global-enterprises-ltd) HCG · quiet · Most evidence points down · 71% evidence 31.1 out of 100 Growth Capital Valuation Relative
20. [Manipal Health Enterprises Ltd](https://www.sectoralpha.in/stocks/manipal-health-enterprises-ltd) MANIPALHOS · Too little evidence to rank firmly · 38% evidence 42.4 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Hospitals](https://www.sectoralpha.in/sectors/hospitals), all 20 compared on one page. ## Which companies are close to Aster DM Quality Care in size? Aster DM Quality Care is the 4th largest of 20 Hospitals companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Apollo Hospitals Enterprise, Manipal Health Enterprises and Max Healthcare Institute. Just below it: Fortis Healthcare, Narayana Hrudayalaya and Global Health. ### Hospitals companies close in size

1. [Apollo Hospitals Enterprise Ltd](https://www.sectoralpha.in/stocks/apollo-hospitals-enterprise-ltd) ₹1,21,469 crore
2. [Manipal Health Enterprises Ltd](https://www.sectoralpha.in/stocks/manipal-health-enterprises-ltd) ₹88,018 crore
3. [Max Healthcare Institute Ltd](https://www.sectoralpha.in/stocks/max-healthcare-institute-ltd) ₹83,705 crore
4. Aster DM Quality Care Ltd ₹59,374 crore
5. [Fortis Healthcare Ltd](https://www.sectoralpha.in/stocks/fortis-healthcare-ltd) ₹57,992 crore
6. [Narayana Hrudayalaya Ltd](https://www.sectoralpha.in/stocks/narayana-hrudayalaya-ltd) ₹35,154 crore
7. [Global Health Ltd](https://www.sectoralpha.in/stocks/global-health-ltd) ₹34,156 crore

[All 20 Hospitals companies, largest first](https://www.sectoralpha.in/sectors/hospitals#all-companies)

### Companies close in size in other industries

1. [APL Apollo Tubes Ltd](https://www.sectoralpha.in/stocks/apl-apollo-tubes-ltd) ₹60,116 crore · Steel - Tubes/Pipes
2. [Oberoi Realty Ltd](https://www.sectoralpha.in/stocks/oberoi-realty-ltd) ₹59,867 crore · Realty - Regional
3. Aster DM Quality Care Ltd ₹59,374 crore
4. [NMDC Ltd](https://www.sectoralpha.in/stocks/nmdc-ltd) ₹59,204 crore · Mining/Minerals - Iron Ore
5. [Torrent Power Ltd](https://www.sectoralpha.in/stocks/torrent-power-ltd) ₹59,103 crore · Power - Generation/Distribution

## What else do people ask about Aster DM Quality Care? ### What is Aster DM Quality Care's share price today? Aster DM Quality Care Ltd's share price is ₹681.35, +0.5% over the past year. The whole company is worth ₹59,405 Cr on the market. In the last 52 weeks it traded between ₹555 to ₹870; today it is 40% of the way up from the low, 4.7% below its 200-day average (as of 3 November 2026). ### What were Aster DM Quality Care's latest quarterly results? Aster DM Quality Care Ltd reported revenue of ₹1,311 Cr and net profit of ₹29.0 Cr for the Jun 2026 quarter. Revenue rose 21.6% and profit fell 69.1% compared with a year earlier. Earnings per share were ₹0.31 (as of 3 November 2026). ### What is Aster DM Quality Care's market cap? Aster DM Quality Care Ltd's market capitalisation is ₹59,405 Cr at a share price of ₹681.35. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Aster DM Quality Care performing? Aster DM Quality Care Ltd's share price has been rising for 34 weeks. In its latest quarter, revenue rose 21.6% and profit fell 69.1% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 6 weeks running (as of 3 November 2026). ### Will Aster DM Quality Care's share price go up? This page does not forecast Aster DM Quality Care Ltd's share price. What it shows instead: the share price is ₹681.35, and it has been rising for 34 weeks. Its P/E of 164.1× is higher than 97% of its own last 8 years (as of 3 November 2026). ### Does Aster DM Quality Care have too much debt? Aster DM Quality Care Ltd has a moderate amount of debt: its debt is 0.62× its equity, and its operating profit is 7 times its interest bill. FY26 borrowings were ₹2,594 Cr against equity of ₹4,201 Cr. Keep that borrowing in mind when reading the returns on this page (as of 3 November 2026). ### What is Aster DM Quality Care's capex? Aster DM Quality Care Ltd sold more long-term assets (plants, machines and the like) than it bought over the last 3 years, by ₹3,936 Cr, worked out from the change in fixed assets plus depreciation. Depreciation over the same years was ₹733 Cr (as of 3 November 2026). ### Where is Aster DM Quality Care in its business cycle? Aster DM Quality Care Ltd's FY26 operating margin was 19.0%, against a 13-year range of 6.0% to 19.0%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 20.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Aster DM Quality Care story? The main question: profits are rising, but only 20% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Aster DM Quality Care a stock worth studying right now? What the numbers show: Aster DM Quality Care Ltd's share price has risen faster than its earnings: +0.5% in a year, against −93.0% for earnings per share. The main open question: whether the cash starts to follow the profit. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Aster DM Quality Care share price forecast for 2026? What management itself guided: Consolidated operating margin to reach 24-25% between FY28 and FY29. ## Lists

- Small & mid cap stocks: https://www.sectoralpha.in/small-cap-stocks-india

This is research, not advice. We’re not SEBI-registered.